Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease

Heerspink et al. (Wed,) studied this question.

www.synapsesocial.com/papers/69d7f43ea2a48916bbbee7ef — DOI: https://doi.org/10.1007/s00125-019-4859-4

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy· 2007 · 91 citations
2. Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic dysfunction· 2010 · 69 citations
3. Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update· 2017 · 520 citations
4. Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes· 2008 · 695 citations
5. Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?· 2013 · 275 citations